Cytotech Labs Unravels Hallmark Insight Into Metabolic Control of Cancer, Presents Work at Major AACR Cancer Meeting`

ORLANDO, Florida, April 4, 2011 - Cytotech Labs, a Boston based pharmaceutical company and member of the
Berg Pharma, Inc. group along with Berg Biosystems and Berg Diagnostics today
presented groundbreaking insight into seminal work performed by Nobel
Laureate, Otto Warburg. The Warburg Hypothesis asserts that increased
utilization of anaerobic respiration and production of lactate is negotiated
by cancer cells in return for evasion of apoptosis, programmed cell death and
other key characteristics of a healthy cell such as normally functioning
mitochondria, the cell's energy and metabolic headquarters. This area of
research has become of intense importance to medical research in the past
decade for many disease states.

(Logo: photos.prnewswire.com/prnh/20110404/CL76842LOGO )

The use of the Berg Biosystems Interrogative Biology(TM) discovery
platform was a vital asset in enabling the biological intelligence necessary
to demonstrate that the molecule ubidecarenone, a coenzyme that shuttles
electrons though mitochondria was depleted in cancer cells but strikingly
created a shift from dependency of lactate production to create a "breach of
contract" between the cancer cell and its preferred metabolic environment.
Dr. Ralph Weichselbaum, D.K. Ludwig Professor and Chairman of Radiation and
Cellular Oncology at the University of Chicago Pritzker School of Medicine
commented, "I have been very intrigued and highly impressed with Cytotech's
innovation and overall approach using the Berg systems biology platform to
develop a whole a new avenue of therapeutic drug discovery."

Original discoverer, Niven R. Narain, now President and CTO of Berg
Biosystems in Boston, founding CTO of Cytotech Labs, and former Director of
Cutaneous Oncology Research at the University of Miami Miller School of
Medicine, where the seminal research on cancer began stated, "It is humbling
to carry on the work of such a great scholar as Otto Warburg to unravel a
mechanism that has escaped us all for so long, using a systems approach
allowed us to appreciate the pressure points in cancer cell metabolism. The
physiologic understanding in bioenergetic alterations that govern gene
regulation opens up new pathways into other disease states such as heart
disease, diabetes, and Alzheimer's."

Cytotech Labs is more advanced in clinical development than any company
focused on cancer metabolism with late stage trials using a topical form of
API 31510 on skin cancer and an on-going Phase I dose escalating, safety and
tolerability trial using a nanodispersion intravenous form of API 31510 for
potential use in advanced solid tumors. Paul Y. Song, Cytotech President and
CMO stated, "As a practicing oncologist who lost his father to cancer, it was
painfully clear that oncology is in dire need of a new treatment paradigm. I
am tremendously excited about our company's innovation and conscious decision
to think outside the box to develop a novel therapeutic frontier."

Cytotech maintains its research and collaborative relationships with the
University of Miami Miller School dating back to license of the technology
from the Department of Dermatology & Cutaneous Surgery led by Dr. Lawrence A.
Schachner, Chairman and Harvey Blank Professor. Mitch Gray, President and CEO
of Pathfinder Management, Inc., the private equity management firm commented,
"We recognized the importance of academia-industry collaboration and have
created a model to succeed on the combined merits of the unified end-point of
patient care." Gray is the visionary that originally met with Narain and his
late mentor and colleague Prof. Emeritus Sung L. Hsia. "To develop a
university-based discovery into a full-fledged clinical program in a few
years is phenomenal," Gray further commented.

Current relationships include Research Associate Professor of Dermatology
and Cutaneous Surgery Dr. Joaquin J. Jimenez, a renowned expert in oncology
animal modeling and chemotoxicity and Associate Dean for International
Medicine and Professor of Medicine, Dr. Eduardo De Marchena who is directing
Cytotech's initiative to perform international clinical trials for its lead
cancer compound API 31510 through the UM International Medicine Institute.

About Cytotech Labs

Cytotech Labs is a discovery driven pharmaceutical company based in
Boston, MA with specific focus on alterations in metabolism as it relates to
disease onset. Notable focus areas are cancer, diabetes, and cardiovascular
disease. The company has a deep pipeline of early-stage technologies that
complement its late-stage clinical trial activity in cancer. Armed with use
of a novel discovery platform licensed from Berg Biosystems that translates
biological output into viable therapeutics and a robust biomarker library,
Cytotech is poised to forge its pursuit of a healthier tomorrow.

About Berg Biosystems

Berg Biosystems is a Boston, Massachusetts based company that employs a
novel approach to systems biology and utilizes systems engineering and
bioinformatic modules to cross-validate biological output. The Berg
Interrogative Biology(TM) Drug Discovery Platform allows for rapid and
precise identification of therapeutic and biomarker candidates for drug
discovery and development. The company uses network biology templates to mine
disease pathophysiology.

About University of Miami Miller School of Medicine

    - The University of Miami Leonard M. Miller School of Medicine, founded
      in 1952, was the first medical school in the state of Florida. The
      Miller School of Medicine is located on the 100-acre University of
      Miami/Jackson Memorial Medical Center complex in Miami. The medical
      center includes three University-owned hospitals that make up the
      University of Miami Health System (UHealth): University of Miami
      Hospital, Sylvester Comprehensive Cancer Center and Bascom Palmer Eye
      Institute. Our three primary affiliated hospitals on the campus include
      Jackson Memorial Hospital, Holtz Children's Hospital and the Miami VA
      Medical Center. Miller School faculty members conduct more than 1,700
      research projects in basic science and clinical care in facilities
      totaling more than 500,000 square feet of research space. Along with
      the M.D. degree, the school offers two specialized B.S./M.D. programs,
      a combined M.D./Ph.D. program, graduate degrees in nine areas,
      postdoctoral programs and continuing medical education courses.

Ashley Potts, +1-617-939-1071